Switch to:
Also traded in: Germany, Japan
» Details

Insider Trades

Latest Guru Trades with SNPHY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:OTCPK:PTKFY, OTCPK:CHJTF, OTCPK:KYKOF, OTCPK:GWPRF, NAS:HCM, OTCPK:MAYNF, OTCPK:HAWPF, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:ASMB, NAS:RMTI, NAS:NBRV, NAS:ZGNX, OTCPK:AGYTF, NAS:OASM, NAS:ALIM, OTCPK:BIOYF, AMEX:NNVC, AMEX:AXN » details
Traded in other countries:SZD.Germany, 4536.Japan,
Santen Pharmaceutical Co Ltd is engaged in research, development, production, marketing of pharmaceuticals & medical devices. Its prescription pharmaceuticals segment is divided into three categories: ophthalmics, anti-rheumatics & other pharmaceuticals.

Santen Pharmaceutical Co Ltd.

Ratios

vs
industry
vs
history
P/E(ttm) 28.40
SNPHY's P/E(ttm) is ranked lower than
53% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.40 vs. SNPHY: 28.40 )
Ranked among companies with meaningful P/E(ttm) only.
SNPHY' s P/E(ttm) Range Over the Past 10 Years
Min: 4.21  Med: 14.83 Max: 32.35
Current: 28.4
4.21
32.35
PE(NRI) 28.40
SNPHY's PE(NRI) is ranked lower than
52% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.84 vs. SNPHY: 28.40 )
Ranked among companies with meaningful PE(NRI) only.
SNPHY' s PE(NRI) Range Over the Past 10 Years
Min: 4.21  Med: 14.83 Max: 32.35
Current: 28.4
4.21
32.35
P/B 2.56
SNPHY's P/B is ranked higher than
56% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. SNPHY: 2.56 )
Ranked among companies with meaningful P/B only.
SNPHY' s P/B Range Over the Past 10 Years
Min: 1.5  Med: 2.04 Max: 3.96
Current: 2.56
1.5
3.96
P/S 3.37
SNPHY's P/S is ranked lower than
53% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. SNPHY: 3.37 )
Ranked among companies with meaningful P/S only.
SNPHY' s P/S Range Over the Past 10 Years
Min: 1.34  Med: 2.57 Max: 9.4
Current: 3.37
1.34
9.4
POCF 133.76
SNPHY's POCF is ranked lower than
94% of the 295 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.98 vs. SNPHY: 133.76 )
Ranked among companies with meaningful POCF only.
SNPHY' s POCF Range Over the Past 10 Years
Min: 9.2  Med: 16.52 Max: 137.45
Current: 133.76
9.2
137.45
EV-to-EBIT 17.31
SNPHY's EV-to-EBIT is ranked higher than
59% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.65 vs. SNPHY: 17.31 )
Ranked among companies with meaningful EV-to-EBIT only.
SNPHY' s EV-to-EBIT Range Over the Past 10 Years
Min: 0.3  Med: 8.6 Max: 42.5
Current: 17.31
0.3
42.5
EV-to-EBITDA 13.51
SNPHY's EV-to-EBITDA is ranked higher than
61% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.72 vs. SNPHY: 13.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNPHY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.3  Med: 7.7 Max: 42.5
Current: 13.51
0.3
42.5
PEG 1.97
SNPHY's PEG is ranked lower than
52% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. SNPHY: 1.97 )
Ranked among companies with meaningful PEG only.
SNPHY' s PEG Range Over the Past 10 Years
Min: 0.21  Med: 1.02 Max: 4.56
Current: 1.97
0.21
4.56
Current Ratio 2.98
SNPHY's Current Ratio is ranked higher than
58% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. SNPHY: 2.98 )
Ranked among companies with meaningful Current Ratio only.
SNPHY' s Current Ratio Range Over the Past 10 Years
Min: 2.08  Med: 4.7 Max: 7.34
Current: 2.98
2.08
7.34
Quick Ratio 2.47
SNPHY's Quick Ratio is ranked higher than
61% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. SNPHY: 2.47 )
Ranked among companies with meaningful Quick Ratio only.
SNPHY' s Quick Ratio Range Over the Past 10 Years
Min: 1.79  Med: 4.09 Max: 6.38
Current: 2.47
1.79
6.38
Days Inventory 124.73
SNPHY's Days Inventory is ranked lower than
55% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. SNPHY: 124.73 )
Ranked among companies with meaningful Days Inventory only.
SNPHY' s Days Inventory Range Over the Past 10 Years
Min: 103.86  Med: 127.36 Max: 168.4
Current: 124.73
103.86
168.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.72
SNPHY's Dividend Yield is ranked higher than
59% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. SNPHY: 1.72 )
Ranked among companies with meaningful Dividend Yield only.
SNPHY' s Dividend Yield Range Over the Past 10 Years
Min: 0.17  Med: 1.94 Max: 3.57
Current: 1.72
0.17
3.57
Dividend Payout 0.46
SNPHY's Dividend Payout is ranked lower than
62% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. SNPHY: 0.46 )
Ranked among companies with meaningful Dividend Payout only.
SNPHY' s Dividend Payout Range Over the Past 10 Years
Min: 0.1  Med: 0.37 Max: 0.55
Current: 0.46
0.1
0.55
Dividend Growth (3y) 7.70
SNPHY's Dividend Growth (3y) is ranked lower than
52% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. SNPHY: 7.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SNPHY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 3.6 Max: 58.7
Current: 7.7
0
58.7
Forward Dividend Yield 1.58
SNPHY's Forward Dividend Yield is ranked higher than
59% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. SNPHY: 1.58 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.20
SNPHY's Yield on cost (5-Year) is ranked higher than
60% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. SNPHY: 2.20 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SNPHY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.22  Med: 2.56 Max: 4.71
Current: 2.2
0.22
4.71
3-Year Average Share Buyback Ratio -0.10
SNPHY's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 436 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. SNPHY: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNPHY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: 0.7 Max: 1.7
Current: -0.1
-0.8
1.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 7.84
SNPHY's Price/Net Current Asset Value is ranked lower than
52% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. SNPHY: 7.84 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SNPHY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.41  Med: 3.68 Max: 12.41
Current: 7.84
2.41
12.41
Price/Tangible Book 4.40
SNPHY's Price/Tangible Book is ranked lower than
57% of the 747 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. SNPHY: 4.40 )
Ranked among companies with meaningful Price/Tangible Book only.
SNPHY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.72  Med: 2.31 Max: 5.68
Current: 4.4
1.72
5.68
Price/Projected FCF 5.54
SNPHY's Price/Projected FCF is ranked lower than
68% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. SNPHY: 5.54 )
Ranked among companies with meaningful Price/Projected FCF only.
SNPHY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.9  Med: 5.53 Max: 14.47
Current: 5.54
1.9
14.47
Price/DCF (Earnings Based) 1.38
SNPHY's Price/DCF (Earnings Based) is ranked lower than
51% of the 78 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. SNPHY: 1.38 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.31
SNPHY's Price/Median PS Value is ranked lower than
61% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. SNPHY: 1.31 )
Ranked among companies with meaningful Price/Median PS Value only.
SNPHY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.57  Med: 1 Max: 3.42
Current: 1.31
0.57
3.42
Price/Peter Lynch Fair Value 1.42
SNPHY's Price/Peter Lynch Fair Value is ranked higher than
55% of the 168 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. SNPHY: 1.42 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SNPHY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.21  Med: 1.06 Max: 4.01
Current: 1.42
0.21
4.01
Price/Graham Number 2.35
SNPHY's Price/Graham Number is ranked lower than
53% of the 443 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. SNPHY: 2.35 )
Ranked among companies with meaningful Price/Graham Number only.
SNPHY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.67  Med: 1.21 Max: 2.76
Current: 2.35
0.67
2.76
Earnings Yield (Greenblatt) (%) 5.81
SNPHY's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. SNPHY: 5.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNPHY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.4  Med: 11.65 Max: 290.4
Current: 5.81
2.4
290.4
Forward Rate of Return (Yacktman) (%) 19.03
SNPHY's Forward Rate of Return (Yacktman) (%) is ranked higher than
69% of the 358 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.67 vs. SNPHY: 19.03 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SNPHY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4  Med: 14.25 Max: 26.7
Current: 19.03
4
26.7

More Statistics

Revenue (TTM) (Mil) $1,808
EPS (TTM) $ 0.52
Beta0.01
Short Percentage of Float0.00%
52-Week Range $11.04 - 16.92
Shares Outstanding (Mil)406.08
» More Articles for SNPHY

Headlines

Articles On GuruFocus.com

More From Other Websites
Santen Pharmaceutical Co., Ltd. :SNPHY-US: Earnings Analysis: Q3, 2017 By the Numbers : February 8,... Feb 08 2017
Santen Pharmaceutical Co., Ltd. : Neutral assessment on price but strong on fundamentals Dec 06 2016
Santen Pharmaceutical Co., Ltd. :SNPHY-US: Earnings Analysis: Q2, 2017 By the Numbers : November 4,... Nov 04 2016
ETF’s with exposure to Santen Pharmaceutical Co., Ltd. : October 6, 2016 Oct 06 2016
Johnson & Johnson Sees Growth in Ophthalmology, Acquires Abbott Medical Optics Sep 16 2016
Santen Pharmaceutical Co., Ltd. :SNPHY-US: Earnings Analysis: Q1, 2017 By the Numbers : August 8,... Aug 08 2016
Santen Pharmaceutical Co., Ltd. : Neutral assessment on price but strong on fundamentals Aug 04 2016
Santen Pharmaceutical Co., Ltd. :SNPHY-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 Jul 26 2016
Santen Pharmaceutical Co., Ltd. : Fairly valued, but don’t skip the other factors May 17 2016
Santen Pharmaceutical Co., Ltd. :SNPHY-US: Earnings Analysis: Q4, 2016 By the Numbers May 17 2016
Here Are 4 Stock Picks if You're Looking Abroad for Growth Apr 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK